Adial Pharmaceuticals
ADIL
22 hedge funds and large institutions have $6.29M invested in Adial Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
126% more call options, than puts
Call options by funds: $154K | Put options by funds: $68K
80% more capital invested
Capital invested by funds: $3.49M → $6.29M (+$2.8M)
0.01% more ownership
Funds ownership: 0.01% → 0.02% (+0.01%)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.98M |
| 2 |
EWM
Empirical Wealth Management
Seattle,
Washington
|
+$76.7K |
| 3 |
Renaissance Technologies
New York
|
+$43.8K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$15.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$56K |
| 2 |
Goldman Sachs
New York
|
-$53K |
| 3 |
RW
Rede Wealth
Charlottesville,
Virginia
|
-$41K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$32K |
| 5 |
BlackRock
New York
|
-$2.74K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Charles Schwab
San Francisco,
California
| – | -$32K | -19 | Closed |
|
ADIL Hedge Fund Activity: Q1 2022 in Review
22 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q1 2022, worth a combined $6.29M — up 80% from $3.49M a quarter earlier.
Fund positioning in ADIL was balanced in Q1 2022: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.98M. The largest seller was Millennium Management, exiting entirely with an estimated $56K sold.
- 22 institutional investors held Adial Pharmaceuticals (ADIL) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $6.29M of Adial Pharmaceuticals stock for Q1 2022, up 80% quarter-over-quarter.
- 4 funds opened new Adial Pharmaceuticals positions in Q1 2022 and 4 closed out, a net change of 0 holders.
- The largest Adial Pharmaceuticals buyer in Q1 2022 was Armistice Capital, an estimated $3.98M added.
- The largest Adial Pharmaceuticals seller in Q1 2022 was Millennium Management, an estimated $56K sold.
Based on aggregated 13F filings for Q1 2022.